Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Recipient : Syntekabio
Deal Size : Undisclosed
Deal Type : Partnership
Syntekabio and Enamine partner for AI-based drug development
Details : The alliance will leverage an extensive synthetic compound library provided by Enamine to support drug candidate discovery services through Syntekabio’s AI platform, DeepMatcher.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 09, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Recipient : Syntekabio
Deal Size : Undisclosed
Deal Type : Partnership